首页> 外文期刊>Bone marrow transplantation >Pre-transplant risk factors for cryptogenic organizing pneumonia/ bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation
【24h】

Pre-transplant risk factors for cryptogenic organizing pneumonia/ bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation

机译:造血细胞移植后隐源性组织性肺炎/闭塞性细支气管炎组织性肺炎的移植前危险因素

获取原文
获取原文并翻译 | 示例
       

摘要

Cryptogenic organizing pneumonia (COP), previously known as bronchiolitis obliterans organizing pneumonia (BOOP), is a significant complication after allogeneic hematopoietic SCT (HCT). However, the pathogenesis of this complication has not yet been elucidated. Therefore, we identified the pre-transplant risk factors for the development of COP/BOOP using the Japan transplant registry database between 2005 and 2009. Among 9550 eligible recipients, 193 experienced COP/BOOP (2%). HLA disparity (odds ratio (OR) 1.51, P=0.05), female-to-male HCT (OR 1.53, P=0.023), and PBSC transplant (OR 1.84, P=0.0076) were significantly associated with an increased risk of COP/BOOP. On the other hand, BU-based myeloablative conditioning (OR 0.52, P=0.033), or fludarabine-based reduced-intensity conditioning (OR 0.50, P=0.0011) in comparison with a TBI-based regimen and in vivo T-cell depletion (OR 0.46, P=0.055) were associated with a lower risk. Of the 193 patients with COP/BOOP, 77 died, including non-relapse death in 46 (59%). Pulmonary failure and fatal infection accounted for 41% (n=19) and 26% (n=12) of the non-relapse death. Allogeneic immunity and conditioning toxicity could be associated with COP/BOOP. Prospective studies are required to elucidate the true risk factors for COP/BOOP and to develop a prophylactic approach.
机译:隐源性组织性肺炎(COP),以前称为闭塞性细支气管炎组织性肺炎(BOOP),是同种异体造血SCT(HCT)后的重要并发症。然而,这种并发症的发病机理尚未阐明。因此,我们使用日本移植注册数据库在2005年至2009年之间确定了COP / BOOP发生的移植前危险因素。在9550名合格接受者中,有193位有经验的COP / BOOP(占2%)。 HLA差异(优势比(OR)1.51,P = 0.05),雌雄HCT(OR 1.53,P = 0.023)和PBSC移植(OR 1.84,P = 0.0076)与COP风险增加显着相关/ BOOP。另一方面,与基于TBI的方案和体内T细胞耗竭相比,基于BU的清髓性调理(OR 0.52,P = 0.033)或基于氟达拉滨的降低强度调理(OR 0.50,P = 0.0011) (OR 0.46,P = 0.055)与较低的风险相关。在193名COP / BOOP患者中,有77例死亡,包括46例(59%)的非复发死亡。肺衰竭和致命感染占非复发死亡的41%(n = 19)和26%(n = 12)。同种异体免疫力和条件毒性可能与COP / BOOP有关。需要进行前瞻性研究以阐明COP / BOOP的真正危险因素,并制定预防措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号